Advert Daiichi Sankyo – Case AUTH/3673/7/22

• Date posted
  27 March 2024
• Sanction
  Advertisement,
• Case number/s
  AUTH/3673/7/22 - Complainant v Daiichi Sankyo

For using a claim which misleadingly implied that Nilemdo (bempedoic acid) could be used therapeutically in combination with any oral lipid lowering treatment without making the contraindication with simvastatin >40mg daily immediately apparent which might prejudice patient safety and was such as to reduce confidence in, and bring discredit upon, the pharmaceutical industry Daiichi Sankyo was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 5.1 - Failing to maintain high standards
Clause 6.1 - Providing misleading information